Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2, Multicenter, Randomized, Parallel, 3-arm, Placebo-controlled Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction (≤ 45%) After Myocardial Infarction

NCT05350969 is registered in ClinicalTrials.gov with Cardior Pharmaceuticals GmbH as lead sponsor.

NCT NCT05350969
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05350969 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2, Multicenter, Randomized, Parallel, 3-arm, Placebo-controlled Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction (≤ 45%) After Myocardial Infarction
Lead sponsor
Cardior Pharmaceuticals GmbH
Phase
Phase 2
Overall status
Completed
Start date
July 11, 2022
Completion date
March 17, 2025
Enrollment
294 (actual)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure, left sided, myocardial infarction, acute